Member Exclusive INTERVIEW

#TalkingRegMed 7: Cell therapy and big pharma with Sven Kili, GSK

​In this exclusive video, Sven Kili, ‎VP and Head of Cell & Gene Therapy Development, GSK, explains why rare diseases are so amenable to treatment with cell therapies.

Go to the profile of RegMedNet
May 09, 2018

Please sign in or register for FREE

Register to RegMedNet

RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.



Go to the profile of James L. Sherley, M.D., Ph.D.

Cell therapy production, tissue stem cell manufacturing in particular, is primarily limited by biology, not cost.

James Sherley at Asymmetrex